Compare

Two terms, side by side

Pick any two terms to see definitions, context, pitfalls, and sources in parallel.

Clinical & Trials

Decentralized Clinical Trial(DCT)

In one line

A trial that uses telehealth, home-based assessments, wearables, and direct-to-patient logistics to reduce or eliminate site visits.

Definition

A Decentralized Clinical Trial (DCT) executes some or all trial activities — consent, screening, assessments, drug or device delivery, data collection — outside traditional brick-and-mortar investigator sites. Common DCT components include eConsent, telehealth visits, home health visits, direct-to-patient shipping of investigational product, wearable and connected sensor data capture, and ePRO. FDA issued a draft DCT guidance in May 2023 and finalized it in September 2024.

Why it matters

DCT components are now standard tools rather than the experimental exception. MedTech-specific DCT use cases include long-term wearable monitoring and remote device-data collection where home use is the actual indication.

Common pitfalls

•Treating DCT as a cost-cutting measure rather than a design choice that can either improve or harm data quality depending on execution.
•Underestimating eConsent regulatory and human-factors validation requirements.

Sources

FDA — Decentralized Clinical Trials Guidance (2024) · FDA
EMA — Recommendation Paper on Decentralised Elements in Clinical Trials · EMA / EC
ICH Guidelines · ICH

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.